Romania Liver Cancer Therapeutics Market Report 2022 to 2030

Romania Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Romania Liver Cancer Therapeutics market will reach a value of $31.6 Mn from $8.5 Mn in 2022, growing at a CAGR of 17.9 % during 2022-2030. Liver Cancer Therapeutics in Romania is dominated by a few domestic pharmaceutical companies such as Biofarm, Antibiotice and Fundeni Clinical Institute. The Liver Cancer Therapeutics market in Romania is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Romania Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10ROPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Dr. Vishwa Modhia

Buy Now

Romania Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Romania Liver Cancer Therapeutics market will reach a value of $31.6 Mn from $8.5 Mn in 2022, growing at a CAGR of 17.9 % during 2022-2030.

Romania is an upper-middle-income, developed country located at the crossroads of Central and Southeastern Europe. After lung cancer, liver cancer is the second leading cause of cancer-related fatalities in Romania. Chronic hepatitis B or C infection, heavy alcohol consumption, obesity, and exposure to aflatoxins are all risk factors for liver cancer. About 15% of the estimated malignancies in Romania were liver cancers caused by alcohol consumption. Toxins in the environment, such as pesticides, industrial chemicals, and heavy metals, can raise the chance of developing liver cancer. Romania has a long history of industrial pollution, which raises the chance of developing liver cancer.

According to the most recent WHO data published in 2020, the number of people dying from liver cancer in Romania reached 3,114, accounting for 1.33 % of all deaths. Romania ranks 45th in the world with an age-adjusted death rate of 8.33 per 100,000 population. Romania’s government spent 6.3 % of its GDP on healthcare in 2020.

romania-liver-cancer-therapeutics-analysis

Market Dynamics

Market Growth Drivers Analysis

According to the Romanian Cancer Registry, there will be roughly 4,700 new cases of liver cancer in Romania in 2020, with an estimated fatality rate of 4,200 persons. Obesity and type 2 diabetes are both risk factors for developing liver cancer. Obesity and diabetes are common in Romania, increasing the risk of liver cancer. Romania has a broad and competitive industry due to its low labour costs. In 2001, the EU included Romania in its "Golden Growth" programme. These aspects could boost Romania's Liver Cancer Therapeutics market.

Market Restraints

In Romania, many occurrences of liver cancer are discovered at a late stage, when treatment options are restricted. In Romania, there is a need for better knowledge of risk factors and early detection measures for liver cancer. Romania's population is declining due to low birth rates and young emigration. These factors may deter new entrants into the Romania Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Fundeni Clinical Institute: Fundeni Clinical Institute is the largest cancer treatment center in Romania, offering comprehensive cancer care, including diagnosis, treatment, and rehabilitation services.
Institute of Oncology Bucharest: The Institute of Oncology Bucharest is another major cancer treatment center in Romania, specializing in the diagnosis and treatment of liver cancer.
Biofarm
Antibiotice
Apceth Biopharma

Healthcare Policies and Reimbursement Scenarios

In Romania, liver cancer treatment is regulated and reimbursed through the national healthcare system. The National Health Insurance Fund (CNAS) is responsible for the reimbursement of healthcare services in Romania, including liver cancer treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.